| 查看: 144 | 回复: 0 | |||
| 当前主题已经存档。 | |||
zhangjh069975银虫 (初入文坛)
|
[交流]
Disruption of the pollen-expressed FERONIA homologs
|
||
|
The precise delivery of male to female gametes during reproduction in eukaryotes requires complex signal exchanges and a flawless communication between male and female tissues. In angiosperms, molecular mechanisms have recently been revealed that are crucial for the dialog between male (pollen tube) and female gametophytes required for successful sperm delivery. When pollen tubes reach the female gametophyte, they arrest growth, burst and discharge their sperm cells. These processes are under the control of the female gametophyte via the receptor-like serine-threonine kinase (RLK) FERONIA (FER). However, the male signaling components that control the sperm delivery remain elusive. Here, we show that ANXUR1 and ANXUR2 (ANX1, ANX2), which encode the closest homologs of the FER-RLK in Arabidopsis, are preferentially expressed in pollen. Moreover, ANX1-YFP and ANX2- YFP fusion proteins display polar localization to the plasma membrane at the tip of the pollen tube. Finally, genetic analyses demonstrate that ANX1 and ANX2 function redundantly to control the timing of pollen tube discharge as anx1 anx2 doublemutant pollen tubes cease their growth and burst in vitro and fail to reach the female gametophytes in vivo. We propose that ANXRLKs constitutively inhibit pollen tube rupture and sperm discharge at the tip of growing pollen tubes to sustain their growth within maternal tissues until they reach the female gametophytes. Upon arrival, the female FER-dependent signaling cascade is activated to mediate pollen tube reception and fertilization, while male ANX-dependent signaling is deactivated, enabling the pollen tube to rupture and deliver its sperm cells to effect fertilization. |
回复此楼» 猜你喜欢
依喜替康：新型喜树碱衍生物的研究进展
已经有1人回复
-
膀胱癌靶向治疗新选择：厄达替尼作用机制与耐药研究进展
已经有0人回复
-
化学工程及工业化学论文润色/翻译怎么收费?
已经有179人回复
-
从水母到实验室：腔肠素的发现历程与生物发光奥秘
已经有1人回复
-
线粒体氧化磷酸化的新靶点：S-Gboxin的发现与研究进展
已经有0人回复
-
PROTAC药物开发选择VHL配体：MDK-7526以87%出口向量占有率成首选
已经有0人回复
-
MCC950：NLRP3炎症小体特异性抑制剂的科研应用与前景
已经有0人回复
-
康替唑胺研发17年：如何解决多重耐药菌感染难题
已经有0人回复
-
伊曲莫德（Etrasimod）从“肠道免疫失控”到精准靶向干预
已经有1人回复
-
西达本胺：创新HDAC抑制剂的抗肿瘤之路
已经有0人回复
